Beckman to Buy DSL, Expand Endocrine Testing

In a move to gain leadership in specialty endocrine testing, Beckman Coulter, Inc. (Fullerton, CA, USA) has agreed to acquire Diagnostic Systems Laboratories Corp. (DSL, Webster, TX, USA). Financial details were not disclosed.

DSL is a leading provider of specialty immunoassays, including proprietary technology for reproductive endocrinology and cardiovascular risk assessment. With 2004 sales of around U.S.$34 million, DSL competes in the specialty endocrinology segment of the immunoassay market. The company markets three proprietary reproductive endocrinology tests, including Inhibin A and B, and anti-Mullerian hormone. In addition, DSL holds exclusive rights to PAPP-A, a marker being evaluated for cardiovascular risk assessment. Currently, endocrinology makes up about 10% of the $5 billion immunoassay market. DSL has satellite laboratories in Germany, the United Kingdom, and Canada.

"DSL is a mature organization with significant scientific and clinical collaboration skills,” said Michael Whelan, group vice president of Beckman Coulter's immunoassay business. "Together we aim to quickly broaden our immunoassay menu and strategically advance our already successful immunoassay franchise.”

DSL has a proven history of collaboration with clinical research leaders to identify new and innovative immunoassays to improve patient care. The company has successfully combined these relationships with a rapid product development process to quickly deliver novel tests to the pharmaceutical and life science research community as well as the traditional clinical laboratory.





Related Links:
Beckman Coulter
DSL